Guilin Sanjin Pharmaceutical Co Ltd (002275) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, manufacturing, and sale of traditional Chinese medicines in China and internationally.
Total Assets Chart for Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co Ltd (002275) total assets for FY2025 were CNY 4.3B, a 0.6% change from FY2024. Guilin Sanjin Pharmaceutical Co Ltd's total assets grew from CNY 831.8M in 2006 to CNY 4.3B in 2025 (411.9% over 19 years). Total assets compound annual growth rate: 5-year CAGR of 1.9%, 10-year CAGR of 4.4%.
Total Assets (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥7.27B
- Implied Share Price
- ¥12.37
- Enterprise Value
- ¥6.20B
- Revenue (TTM)
- ¥2.02B
- EBITDA
- ¥646.32M
- Profit Margin
- 20.19%
- Trailing P/E
- 17.93
- Forward P/E
- 19.96
- Price/Book (MRQ)
- 2.23
- Price/Sales (TTM)
- 3.61
- EV/EBITDA
- 9.22
- EV/Revenue
- 3.07
- Dividend Yield
- 4.02%
- Book Value
- ¥5.51
- Free Cash Flow (FY2025)
- ¥621.18M
- Free Cash Flow Yield
- 8.55%
Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.